Immunotherapy for Solid Tumor Malignancies in Pediatrics Using Interleukin-15 and -21 Armored Glypican-3-specific Chimeric Antigen Receptor T Cells
Phase 1
21
about 18 years
1–26
1 site in WA
What this study is about
Researchers are testing a new treatment, SC-CAR.GPC3xIL15.21 CAR T cells, to see if it's safe and effective for children with certain types of solid tumors that don't have cancer in the brain or spinal cord. The trial will involve collecting blood samples from eligible participants to create personalized CAR T cells targeting their specific tumor.
Simplified from trial records by PatientMatch.
What you may be asked to do
- 1.Receive SC-CAR.GPC3xIL15.21 CAR T cells
Participation Burden
What's physically and logistically required of participants.
Requires travel to a study site
How treatment is administered
Everyone gets the investigational treatment.
Extracted study details
Pulled from the trial record to show what is being tested and what the study is measuring.
cell therapy (Engineered T-cells that target specific cancer antigens)
subcutaneous
Primary: Establish the safety, defined by adverse events of SC-CAR.GPC3xIL15.21 T cells.
Secondary: Estimate the maximum tolerated dose (MTD) or biologically effective dose and dose limiting toxicities (DLT), and describe the full toxicity profile of SC-CAR.GPC3xIL15.21 T cells.
Oncology